COVID-19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post-Pandemic Concerns About the Impact of Rituximab.
Christian AmmitzbøllMarianne Kragh ThomsenLars Erik BartelsCecilie Bo HansenMarie-Louise From HermansenMathias HänelRasmus Klose-JensenMads Lamm LarsenMorgan Oliver LauritsenClara Mistegård JørgensenSusan MikkelsenJanne Bille Mønster OlesenEsben Uggerby NæserMorten Aagaard NielsenChristian ErikstrupPeter GarredEllen Margrethe HaugeAnne TroldborgPublished in: ACR open rheumatology (2024)
Vaccinating before RTX initiation yields a robust serological response in patients with AIIRDs. Furthermore, we highlight the reversibility of antibody impairment after RTX treatment cessation, provided that adequate vaccinations occur within a minimum of 9 months after RTX. Our findings offer essential insights for clinical decision-making regarding COVID-19 vaccination and RTX treatment, alleviating concerns about future RTX use.